Sudden death in dilated cardiomyopathy

Related Experiment Video

Updated: Oct 23, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

A H Wu1, S K Das

  • 1Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109, USA.

Clinical Cardiology
|April 13, 1999
PubMed

Insights

Sudden death in dilated cardiomyopathy (DCM) is often caused by ventricular arrhythmias. While ACE inhibitors improve survival, the roles of newer drugs and devices for arrhythmias in DCM require further investigation.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Pharmacology

Background:

  • Dilated cardiomyopathy (DCM) is a significant cause of heart failure and sudden cardiac death.
  • Arrhythmias, particularly ventricular arrhythmias, are a major contributor to mortality in DCM patients.

Purpose of the Study:

  • To review the role of arrhythmias in sudden death among patients with dilated cardiomyopathy.
  • To discuss current and emerging treatment strategies for managing arrhythmias in DCM.

Main Methods:

  • Comprehensive literature search of MEDLINE database (1985-present) and relevant article citations.
  • Analysis of studies on the pathophysiology, prognostic significance, and management of arrhythmias in DCM.

Main Results:

  • Ventricular arrhythmias are the primary cause of sudden death in DCM, with ventricular ectopy potentially indicating risk.
  • Autonomic nervous system and renin-angiotensin-aldosterone axis abnormalities contribute to ventricular arrhythmias.
  • Electrophysiologic studies and signal-averaged electrocardiography have uncertain roles in risk stratification.

Conclusions:

  • Ventricular tachyarrhythmia is the main pathophysiological mechanism for sudden death in DCM.
  • Angiotensin-converting enzyme inhibitors are crucial for improving overall mortality.
  • Ongoing research is evaluating amiodarone, angiotensin-receptor antagonists, beta-blockers, and implantable cardioverter-defibrillators for arrhythmia management in DCM.

More Related Videos

Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits06:46

Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits

Published on: February 28, 2025

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...